ADVERTISEMENT
ADVERTISEMENT

Lonza and AllCells Join Forces for Global Commercialization of Hematopoietic Primary Cells

Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables cell biologists to easily access a wide selection of high-quality cells to boost their scientific research.

Lonza

Under the new agreement, the entire AllCells research portfolio of products will bear the Lonza branding and will allow scientists on a global scale to further their research across an array of applications, including drug discovery, toxicity testing, cell therapy and personalized medicine. 

Hematopoietic primary cells play a vital role in advancing in vitro research as they closely reflect in vivo morphology, metabolism and growth characteristics. However, obtaining those cells requires researchers to find a variety of donors and perform a series of tedious cell isolations. 

“With this partnership, we aim to enable straightforward access to a wealth of viable, ready-to-use hematopoietic cells, such as mobilized peripheral blood progenitor cells,” said Mary Riley, Director of Discovery Solutions at Lonza. “All researchers will need to do is thaw and culture, while also being able to take advantage of Lonza’s strong after-sales technical support.”

Don Klabunde, CEO at AllCells, added: “By leveraging...

Further information can be found via www.lonza.com/hematopoietic-products 

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT